Treatment of warts by Topical retinoids: An Exploration and meticulosity

Authors

  • Ruchi Tiwari Pranveer Singh Institute of Technology, Kanpur - Agra - Delhi National Highway - 2, Bhauti, Kanpur, India.
  • Gaurav Tiwari Pranveer Singh Institute of Technology, Kanpur - Agra - Delhi National Highway - 2, Bhauti, Kanpur, India.
  • Pranay Wal Pranveer Singh Institute of Technology, Kanpur - Agra - Delhi National Highway - 2, Bhauti, Kanpur, India.
  • Ankita Wal Pranveer Singh Institute of Technology, Kanpur - Agra - Delhi National Highway - 2, Bhauti, Kanpur, India.

Keywords:

Antiquity of warts, Diagnosis, Topical retinoids and its mechanism of action, Exploration of tretinoin

Abstract

Warts are clinically skin infections caused by Human Papilloma Virus (HPV). Some warts are painful while others cause frustration in patients. Warts are contagious and need to be diagnosed clinically from the outgrowth of skin. Topical retinoids have clinical use for treatment of chronic skin conditions. Topical retinoids for treatment of skin cancer are tretinoin, the acid form of vitamin A, also known as all-trans retinoic acid, which is the active vitamin A metabolite in several tissues, isotretinoin (13-cis-retinoic acid), and two third-generation retinoids, adapalene and tazarotene. Vitamin A is necessary for the growth and differentiation of epithelial tissues. Retinoids influence the process of vitamin A by interacting with specific cellular and nuclear receptors of skin. In that way retinoids control cell proliferation and differentiation and potentially interfere with the tumor promotion phase of carcinogenesis by inducing apoptosis. Review of medical literatures from past few years revealed monotherapies and combination therapies to eradicate viral infections caused by HPV. Purpose of this review article is to provide general information about warts, its mechanism and treatment by topical retinoids.

References

1. Skin Problems and Treatments [Internet]. WebMed; [Cited 2016 July 12]. Available from: http://www.
webmd.com/skin-problems-and-treatments/warts.
2. Bruggink SC, de Koning MN, Gussekloo J, Egberts PF, Ter Schegget J, Feltkamp MC, Bavinck JN, Quint WG, Assendelft WJ, Eekhof JA. Cutaneous wartassociated HPV types: Prevalence and relation with patient Characteristics. Journal of Clinical Virology 2012; Nov;55(3):250-5.
3. Shayanfar N, Hosseini N, Panahi M , Azadmanesh K, Mohammadpour M, Kadivar M, Mirzaie AZ , Sohrabi
A. Detection of mucosal type human papillomavirus in cutaneous squamous cell carcinoma in Iran. Pathology – Research and Practice 2013; 209(2):90-4.
4. Devi LT, Pathania K. Pregnancy with HPV associated Viral Warts. MJAFI 2009; July;65:272-3.
5. Jabeotiska S, Majewski S, Obalek S, Orth G. Cutaneous Warts. Clinics in dermatology. 1997 May-June;15(3):
309-19.
6. Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association
of Dermatologists’ Guidelines for the Management of Cutaneous Warts. The British Journal of Dermatology 2014; Oct;171(4):696-712.
7. Zur Hausen H. Papillomaviruses in the causation of human cancers- a brief historical account. Virology
2009; Feb;384(2):260-5.
8. Parmar D, Shah J. Cutaneous Warts and its Treatment: A Literature Review. International Journal of Science and Research 2015; September;4(9):87-89.
9. Shapiro S, Heremans A, Mays DA, Martin AL, Hernandez- Medina M, Lanes S. Use of topical tretinoin and the
development of noncutaneous adverse events: Evidence from a systematic review of the literature. J
Am Acad Dermatol 2011; Dec;65(6):1194-201.
10. Ouriquea A, Pohlmannb AR, Guterresc SS, Beckd RCR. Tretinoin-loaded nanocapsules: Preparation, physicochemical characterization, and photostability study. International Journal of Pharmaceutics 2008; April;352(1-2):1–4.
11. Tian Y, Zhong S, Huang A, Pann Y, Wang X. Large pore size FeNi carbon microspheres: Synthesis and tretinoin adsorption behavior. Materials Letters. 2015;141:10–13.
12. Tashtoush BM, Jacobson EL, Jacobson MK. A rapid HPLC method for simultaneous determination of tretinoin and isotretinoin in dermatological formulations. Journal of Pharmaceutical and Biomedical Analysis. J Pharm
Biomed Anal 2007; Feb;43(3):859-64.
13. Ascenso A, Salgado A, Euleterio C, Praca FG, Bentley MV, Marques HC, Oliveira H, Santos C, Simoes S. In vitro and in vivo topical delivery studies of tretinoinloaded ultradeformable vesicles. European Journal of Pharmaceutics and Biopharmaceutics 2014; 88(1):48–55.
14. Manconi M, Sinico C, Caddeo C, Vila AO, Valenti D, Fadda AM. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin. Int J Pharm 2011; Jun;412(1-2):37-46.
15. Berger R, Rizer R, Barba A, Wilson D, Stewart D, Grossman R, Nighland M, Weiss J. Tretinoin Gel
Microspheres 0.04% Versus 0.1% in Adolescents and Adults with Mild to Moderate AcneVulgaris: A 12-Week,
Multicenter, Randomized, Double-Blind, Parallel-Group, Phase IV Trial. Clin Ther 2007; Jun;29(6):1086-97.
16. Micali G, Lacarrubb F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer. J Am Acad Dermatol
2014; June;70(6):965.e1-965.e10.
17. Leon H. Kircik MD. Evaluating Tretinoin Formulations in the Treatment of Acne. J Drugs Dermatol 2014;
13(4):466-470.
18. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical
delivery. International Journal of Pharmaceutics 2007;345;163–71.
19. Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. Niosomes as carriers for tretinoin III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. International Journal of Pharmaceutics
2006;311:11–19.
20. Lai F, Pireddu R, Corrias F, Fadda AM, Valenti D, Pini E, Sinico C. Nanosuspension improves tretinoin
photostability and deliveryto the skin. International Journal of Pharmaceutics 2013;458:104 -09.

Downloads

Published

2018-10-26

How to Cite

Tiwari, R., Tiwari, G., Wal, P., & Wal, A. (2018). Treatment of warts by Topical retinoids: An Exploration and meticulosity. Journal of Drug Discovery and Development ( ISSN:2581-6861), 1(1), 48-53. Retrieved from https://medicaljournalshouse.com/index.php/JDrug-Discovery-Development/article/view/54

Issue

Vol. 1 No. 1 (2017): Journal of Drug Discovery and Development

Section

Articles

License

We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________

Important

(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.

(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.

(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.